CBIO: the cashflow

MyFinsight

For the quarter ending 2025-09-30, CBIO had -$19,379K decrease in cash & cash equivalents over the period. -$18,125K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-61,545	-
Share-based compensation expense	1,986	6,569
Depreciation expense	28	2
Non-cash interest expense	0	2,185
Non-cash research and development expense related to paragon option agreement	0	-
Non-cash lease expense	94	23
Accounts payable-Nonrelated Party	1,488	-431
Accrued expenses and other current liabilities-Nonrelated Party	2,005	4,417
Related party accounts payable and other current liabilities-Related Party	1,090	-2,038
Operating lease liability	46	14
Prepaid expenses and other current assets	-284	1,134
Other assets	-47	-78
Net cash used in operating activities	-17,539	-27,253
Purchases of property and equipment	586	140
Net cash used in investing activities	-586	-140
Proceeds from the pre-closing financing, net	-1,254	144,281
Cash acquired in connection with the reverse recapitalization	0	1,269
Proceeds from early exercise of options	0	5
Repurchase of equity awards	0	-177
Net cash provided by financing activities	-1,254	145,378
Net increase in cash, cash equivalents, and restricted cash	-19,379	117,985
Cash and cash equivalents at beginning of period	34,766	-
Cash and cash equivalents at end of period	133,372	-

Unit: Thousand (K) dollars